hepatocellular carcinoma
Conditions
Interventions
Sponsors
Zhongshan Hospital affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old; 2. Patients with hepatocellular carcinoma confirmed by pathological examination and who had received liver transplantation had no great vascular infiltration, no lymph node or extrahepatic metastasis. 3. Above Milan standard (Milan standard: diameter of single tumor nodule =1 /5ml peripheral blood, scoring patients at high risk; 4. Child-pugh liver function rating: Grade A or better Grade B (=90 g/L; ANC >=1.5x10^9/L; PLT >=75x10^9/L; (2) Biochemical examination: ALB >=28 g/L; ALT and AST< 5 ULN; TBIL <=2 ULN; Creatinine <=1 ULN; 8. Subjects voluntarily participate in this study, sign the informed consent form, have good compliance and cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Pathological diagnosis was intrahepatic cholangiocarcinoma, mixed cell carcinoma or fibre-laminar cell carcinoma; 2. Previous or concurrent malignancies (except cured basal cell carcinoma of skin and carcinoma in situ of the cervix); 3. Patients with multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction); 4. In 6 months, the patient has experienced ANY ARTERiovenous thrombosis events, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism; 5. History of gastrointestinal bleeding caused by severe gastroesophageal varices or clear tendency of gastrointestinal bleeding;Or definite tendency of gastrointestinal bleeding due to other causes, such as active ulcer, ulcerative colitis, etc.Fecal occult blood ++ or above, if +, gastroscopy is required; 6. any of the following coagulation abnormalities: prothrombin time (PT) > 16 s, activated partial thrombin time (APTT) > 43 s, thrombin time (TT) > 21 s, INR > 2, fibrinogen (FIB) =150 mmHg or diastolic pressure >=100 mmHg); Having grade I or above myocardial ischemia or infarction, arrhythmia (including QTc interval >=480ms) and grade I cardiac insufficiency;LVEF (left ventricular ejection fraction) 10 mmol/L; (4) urine routine indicated urinary protein >=++, and confirmed 24-hour quantitative urinary protein > 1.0g; 8. There is an unhealed wound, ulcer or fracture; 9. Persons who have a history of abuse of psychotropic substances and cannot be cured or have mental disorders; 10. A history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 11. According to the researcher's judgment, there are other patients who are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Effects Rate;Duration of medication; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-free survival time;Overall survival; | — |
Countries
China
Contacts
Public ContactJian Sun
Zhongshan Hospital affiliated to Fudan University
Outcome results
None listed